Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
Open Access
- 1 December 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (12) , 3904
Abstract
Autologous serum eyedrops (ASE) are effective in treating various ocular surface diseases, including damages induced by long-term use of preserved glaucoma eyedrops. However, there has been no study on whether ASE is effective without stopping the causative eyedrops. This retrospective observational study included 55 patients with ocular-surface diseases caused by long-term use of preserved glaucoma eyedrops: 18 patients who used ASEs for 2 months without discontinuing the use of glaucoma eyedrops (Group 1), 22 patients who used ASEs for 2 months, discontinuing the use of glaucoma eyedrops for the first month (Group 2) and 15 patients who used non-preservative artificial tears for 2 months, discontinuing the use of glaucoma eyedrops for the first month (Group 3). There were no intergroup differences in the baseline values of the Schirmer I test results, tear breakup time (TBUT), ocular surface staining (OSS) score, loss of the meibomian gland, meibum quality and ocular-surface disease index (OSDI). Group 1 showed significant differences in TBUT, OSS score and OSDI at 2 months when compared to the baseline values before treatment, while Group 2 showed significant differences in those values at both 1 and 2 months. There were no differences in any of the parameters at baseline, 1 month or 2 months in Group 3. Our result suggested that ASE is effective for treating ocular surface diseases caused by glaucoma eyedrops containing preservatives and its effects can be expected without interruption of glaucoma eyedrop treatment.Keywords
Funding Information
- National Research Foundation of Korea (2015R1C1A1A01054947)
This publication has 29 references indexed in Scilit:
- Current Evidence on the Ocular Surface Microbiota and Related DiseasesMicroorganisms, 2020
- Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCTHealth Technology Assessment, 2019
- The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A reviewJournal of Current Ophthalmology, 2019
- Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensive TherapyAdvances in Therapy, 2018
- Effects of artificial tears on ocular surface in glaucomatous patients with long-term instillation of preserved antiglaucoma eye dropsRussian Annals of Ophthalmology, 2018
- Ocular Surface Disease in Patients under Topical Treatment for GlaucomaEuropean Journal of Ophthalmology, 2017
- Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)Expert Opinion on Drug Metabolism & Toxicology, 2016
- Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trialsClinical Ophthalmology, 2016
- Glaucoma therapy and ocular surface diseaseCurrent Opinion in Ophthalmology, 2013
- Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBritish Journal of Ophthalmology, 2002